Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort

Lupus

Volumn 11, Issue 6, 2002, Pages 356-361

  Molad, Y ^a   Gorshtein, A ^a,b   Wysenbeek, A J ^b   Guedj, D ^a   Majadla, R ^a   Weinberger, A ^a   Amit Vazina, M ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Activity; Antimalarial therapy; Damage; Hydroxychloroquine; Lupus

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE;

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; DISEASE ACTIVITY; FEMALE; HUMAN; ISRAEL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTIMALARIALS; ANTIRHEUMATIC AGENTS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; HYDROXYCHLOROQUINE; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0036309793     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203302lu203ra     Document Type: Article

References (48)

1. The development and validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus
2. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus
3. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic lupus erythematosus International comparison
4. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population
5. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus
6. Socioeconomic status and health in women with systemic lupus erythematosus
7. The association of socioeconomic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus
8. Association between clinical factors, socioeconomic status, and organ damage in recent onset systemic lupus erythematosus
9. SLICC/ACR Damage Index in Afro-Caribbean patients with systemic lupus erythematosus: Changes in and relationship to disease activity, corticosteroid therapy, and prognosis
10. Disease course in systemic lupus erythematosus: Changes in health status, disease activity, and organ damage after 2y
11. Antimalarial agents and lupus
12. A randomized study on the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus
13. A long term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus
14. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids
15. Hydroxychloroquine use in the Baltimore Lupus Cohort: Effects on lipids, glucose and thrombosis
16. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus
17. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs
18. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus
19. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?
20. The 1982 revised criteria for the classification of systemic lupus erythematosus
21. Derivation of the SLEDAI: A disease activity index for lupus patients
22. Early damage as measured by the SLICC/ACR Damage Index is a predictor of mortality in systemic lupus erythematosus
23. Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: Relationship with disease duration
24. Do present damage and health perception in patients with systemic lupus erythematosus predict extent of future damage? A prospective study
25. Impact of disease activity and cumulative damage on the health of lupus patients
26. Lack of correlation among the 3 outcomes describing SLE: Disease activity, damage and quality of life
27. Features of SLE in various ethnic groups in Israel
28. Increased risk of cancer in patients with systemic lupus erythematosus
29. Malignancy in systemic lupus erythematosus
30. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus
31. Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review
32. The bimodal mortality of systemic lupus erythematosus
33. Corticosteroid induced morbidity in SLE
34. Risk factors for coronary artery disease in patients with systemic lupus erythematosus
35. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study
36. Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: A quality improvement study
37. Accelerated atheroma in lupus- Background
38. Damage in systemic lupus erythematosus and its association with corticosteroids
39. The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in premenopausal women
40. Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids
41. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: An update
42. Trabecular and cortical bone loss in systemic lupus erythematosus
43. Frequency of fractures in women with systemic lupus erythematosus: Comparison with United States population data
44. Risk factors for vascular bone necrosis in systemic lupus erythematosus
45. Risk factors for osteonecrosis in systemic lupus
46. Avascular necrosis in patients with SLE; Relation to corticosteroid therapy and anticardiolipin antibodies
47. Vascular stiffness with systemic lupus erythematosus
48. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus